BCDA
BioCardia, Inc.
There isn't enough reported data to score BCDA yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
BCDA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
BCDA's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
BCDA PE Valuation
BCDA has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
BCDA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect BCDA's losses to shrink, with revenue holding steady.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
BCDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.46 | +$2.09 |
| Q2 2026 | -$0.58 | +$2.34 |
| Q1 2026 | -$0.85 | +$2.55 |
| Q4 2025 | -$1.23 | +$2.93 |
| Q3 2025 | -$2.55 | +$1.64 |
| Q2 2025 | -$2.92 | +$2.46 |
| Q1 2025 | -$3.40 | +$3.65 |
| Q4 2024 | -$4.16 | +$4.09 |
BCDA is still losing money, but far less than before: $0.46 per share over the past year, against $39.15 at its worst in late 2019.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over BCDA on earnings quality, reporting a profit while its opponent remains loss making.
BCDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2024 | $3K | -93% |
| Q1 2024 | $55K | -14% |
| Q4 2023 | $13K | -88% |
| Q3 2023 | $357K | +68% |
| Q2 2023 | $43K | -96% |
| Q1 2023 | $64K | +6.7% |
| Q4 2022 | $106K | +34% |
| Q3 2022 | $212K | -74% |
BCDA's revenue has slid since its 2022 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2024 | -54967% | -46939 points |
| Q1 2024 | -4136% | +1348 points |
| Q4 2023 | -16031% | -13184 points |
| Q3 2023 | -728% | +716 points |
| Q2 2023 | -8028% | -7772 points |
| Q1 2023 | -5484% | +61 points |
| Q4 2022 | -2847% | +1534 points |
| Q3 2022 | -1443% | -1114 points |
BCDA's operating margin was −54967% last quarter, down 46939 points from the same quarter a year ago, near the bottom of its range since 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
BCDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.7M | -$49K |
| Q1 2026 | -$1.7M | -$44K |
| Q4 2025 | -$2.5M | +$71K |
| Q3 2025 | -$1.7M | +$941K |
| Q1 2025 | -$1.6M | -$88K |
| Q4 2024 | -$2.6M | -$723K |
| Q3 2024 | -$2.6M | -$201K |
| Q2 2024 | -$1.3M | +$1.8M |
BCDA has burned cash in almost every quarter: −$8M over the past year, against −$8M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over BCDA on cash generation, producing positive trailing cash flow while its opponent burns cash.
BCDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +25% | +3M shares |
| 1 year | +199% | +10.1M shares |
| 3 years | +1181% | +14M shares |
| 5 years | +1699% | +14.3M shares |
BCDA has 15M diluted shares, up 199% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over BCDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
BCDA Net Leverage
BCDA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
BCDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.2 | Neutral |
| Stochastic | 15.1 | Oversold |
BCDA's weekly RSI is 38 (neutral) and its Stochastic is 15 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
BCDA PE vs Healthcare Sector
BCDA has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
BCDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.94 | 12% below |
| 20 week MA | $0.98 | 15% below |
| 50 week MA | $1.10 | 25% below |
| 100 week MA | $1.57 | 47% below |
UNH has stronger trend alignment. BCDA is above 0 of 4 weekly averages versus UNH above 4 of 5.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
BCDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $17.6 | $9.96 | -43% |
| 2024 | $9.96 | $2.46 | -75% |
| 2025 | $2.46 | $1.27 | -48% |
| 2026 YTD | $1.27 | $0.83 | -35% |
BCDA has finished every year since 2023 lower, and it's down 35% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over BCDA on returns for 2026, with the stronger performance.